Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells

Mototsugu Oya, Masafumi Ohtsubo, Atsushi Takayanagi, Masaaki Tachibana, Nobuyoshi Shimizu, Masaru Murai

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-κB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-κB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IκBα, a specific inhibitor of NF-κB, in TRAIL-sensitive cell lines with a low NF-κB activity result in constitutive activation of NF-κB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IκBα in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-κB activity and TRAIL-resistant RCC with constitutively activated NF-κB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-κB appears to be a promising therapy.

Original languageEnglish
Pages (from-to)3888-3896
Number of pages9
JournalOncogene
Volume20
Issue number29
DOIs
Publication statusPublished - 2001 Jun 28

Fingerprint

Renal Cell Carcinoma
Apoptosis
Cell Line
Death Domain Receptors
Neoplasms
Complementary DNA
Therapeutics

Keywords

  • Apoptosis
  • IκBα
  • NF-κB
  • Renal cell carcinoma
  • TRAIL

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Oya, M., Ohtsubo, M., Takayanagi, A., Tachibana, M., Shimizu, N., & Murai, M. (2001). Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene, 20(29), 3888-3896. https://doi.org/10.1038/sj.onc.1204525

Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells. / Oya, Mototsugu; Ohtsubo, Masafumi; Takayanagi, Atsushi; Tachibana, Masaaki; Shimizu, Nobuyoshi; Murai, Masaru.

In: Oncogene, Vol. 20, No. 29, 28.06.2001, p. 3888-3896.

Research output: Contribution to journalArticle

Oya, M, Ohtsubo, M, Takayanagi, A, Tachibana, M, Shimizu, N & Murai, M 2001, 'Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells', Oncogene, vol. 20, no. 29, pp. 3888-3896. https://doi.org/10.1038/sj.onc.1204525
Oya, Mototsugu ; Ohtsubo, Masafumi ; Takayanagi, Atsushi ; Tachibana, Masaaki ; Shimizu, Nobuyoshi ; Murai, Masaru. / Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells. In: Oncogene. 2001 ; Vol. 20, No. 29. pp. 3888-3896.
@article{9de00ef2cfd541b19f3fe52c7f708227,
title = "Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells",
abstract = "TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-κB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-κB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IκBα, a specific inhibitor of NF-κB, in TRAIL-sensitive cell lines with a low NF-κB activity result in constitutive activation of NF-κB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IκBα in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-κB activity and TRAIL-resistant RCC with constitutively activated NF-κB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-κB appears to be a promising therapy.",
keywords = "Apoptosis, IκBα, NF-κB, Renal cell carcinoma, TRAIL",
author = "Mototsugu Oya and Masafumi Ohtsubo and Atsushi Takayanagi and Masaaki Tachibana and Nobuyoshi Shimizu and Masaru Murai",
year = "2001",
month = "6",
day = "28",
doi = "10.1038/sj.onc.1204525",
language = "English",
volume = "20",
pages = "3888--3896",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "29",

}

TY - JOUR

T1 - Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells

AU - Oya, Mototsugu

AU - Ohtsubo, Masafumi

AU - Takayanagi, Atsushi

AU - Tachibana, Masaaki

AU - Shimizu, Nobuyoshi

AU - Murai, Masaru

PY - 2001/6/28

Y1 - 2001/6/28

N2 - TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-κB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-κB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IκBα, a specific inhibitor of NF-κB, in TRAIL-sensitive cell lines with a low NF-κB activity result in constitutive activation of NF-κB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IκBα in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-κB activity and TRAIL-resistant RCC with constitutively activated NF-κB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-κB appears to be a promising therapy.

AB - TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-κB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-κB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IκBα, a specific inhibitor of NF-κB, in TRAIL-sensitive cell lines with a low NF-κB activity result in constitutive activation of NF-κB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IκBα in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-κB activity and TRAIL-resistant RCC with constitutively activated NF-κB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-κB appears to be a promising therapy.

KW - Apoptosis

KW - IκBα

KW - NF-κB

KW - Renal cell carcinoma

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=0035963273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035963273&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1204525

DO - 10.1038/sj.onc.1204525

M3 - Article

VL - 20

SP - 3888

EP - 3896

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 29

ER -